Research and Surveys
The British Skin Foundation is currently supporting research at Cardiff University.
1 in 5 adults will develop a basal cell carcinoma in their lifetime, with surgery currently the main treatment since alternative therapies are not universally effective. Recently identified cancer stem cells in basal carcinoma drive tumour growth and are responsible for cancer drug resistance. However, multiple lines of evidence support the use of therapies that enhance the immune response as a strategy to treat basal cell carcinoma.
The study at Cardiff University is investigating whether targeting cancer stems cells is sufficient to evoking an immune response to cure basal cell carcinoma, without surgery.
Courtesy of the British Skin Foundation
For further information click here.
Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello. We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support.
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361